| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C648667-5mg |
5mg |
期货  |
| |
| C648667-10mg |
10mg |
期货 |
|
| 英文别名 | PD039943 | 1(2H)-Quinolinecarboxylic acid, 4-(acetyl((3,5-bis(trifluoromethyl)phenyl)methyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-methylethyl ester, (2R,4S)- | CP 532623, >=98% (HPLC) | (2R,4S)-4-(Acetyl(3,5-bis(trifluoromethyl)benzyl)amino)- |
|---|---|
| 英文名称 | CP-532623 |
| 生化机理 | CP-532623 是一种 CETP 抑制剂，可提高高密度脂蛋白胆固醇含量。CP-532623 是 Torcetrapib 的近似结构类似物。CP-532623 具有高亲脂性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties In Vitro CP-532623 is highly lymphatically transported (28% of dose), and lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions and poorly relates to solubility in mixtures of lipoprotein core and/or surface lipids. CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CP-532623 (50 mg; oral administration; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively). Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male greyhound dogs (27-39 kg)Dosage: 50 mg Administration: Oral administration with a long-chain lipid formulation to fed lymphcannulated Result: Substantially transported into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhanced oral bioavailability and the proportion of the absorbed dose transported via the lymph. Form:Solid IC50& Target:CETP |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | propan-2-yl (2R,4S)-4-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate |
| INCHI | 1S/C27H27F9N2O3/c1-5-20-12-23(21-11-17(25(28,29)30)6-7-22(21)38(20)24(40)41-14(2)3)37(15(4)39)13-16-8-18(26(31,32)33)10-19(9-16)27(34,35)36/h6-11,14,20,23H,5,12-13H2,1-4H3/t20-,23+/m1/s1 |
| InChi Key | TUPKOWFPVAXQFP-OFNKIYASSA-N |
| Smiles | CCC1CC(C2=C(N1C(=O)OC(C)C)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C |
| Isomeric SMILES | CC[C@@H]1C[C@@H](C2=C(N1C(=O)OC(C)C)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)C |
| PubChem CID | 10145345 |
| 分子量 | 598.5 |
| 分子量 | 598.500 g/mol |
|---|---|
| XLogP3 | 7.100 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 12 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 598.188 Da |
| 单同位素质量Monoisotopic Mass | 598.188 Da |
| 拓扑极表面积Topological Polar Surface Area | 49.900 Ų |
| 重原子数Heavy Atom Count | 41 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 899.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P330: 漱口 P501: 将内容物/容器处理到。。。 P301+P317: 如果被吞咽：请寻求医疗帮助。 |
| WGK Germany | 3 |
| RIDADR | NONHforallmodesoftransport |
首页
400-620-6333
